5-Amino-1MQ and SLU-PP-332 are both studied as "exercise mimetics" — compounds that recreate some of the gene-level effects of training. But they reach that goal through very different routes.
What They Share
Both compounds target metabolism in mouse models. Both have shown improvements in fat handling, energy use, and endurance markers in preclinical studies. And both have been described in the literature as exercise mimetic candidates.
That label is loaded. It does not mean either compound replaces a workout. It means each one switches on some of the same genes that exercise switches on. The list of effects is much narrower than what real training produces.
How 5-Amino-1MQ Works
5-Amino-1MQ is a small-molecule inhibitor of an enzyme called NNMT (nicotinamide N-methyltransferase). NNMT consumes methyl groups and nicotinamide, a precursor in the NAD+ pathway. When NNMT activity is high, it indirectly drains the NAD+ pool.
By blocking NNMT, 5-Amino-1MQ helps preserve NAD+. Work by Neelakantan and colleagues (2018) showed that NNMT inhibition reduced fat mass in obese mice and improved metabolic parameters. The mechanism is indirect — the compound doesn't add NAD+, it stops something that wastes it.
How SLU-PP-332 Works
SLU-PP-332 takes a more direct route. It activates a family of nuclear receptors called estrogen-related receptors (ERRs), specifically ERR-alpha, beta, and gamma. These receptors are master regulators of mitochondrial biogenesis and oxidative metabolism.
When ERRs activate, they switch on genes that build new mitochondria, oxidize fatty acids, and improve oxidative phosphorylation. These are some of the same gene programs that endurance exercise turns on. Billon and colleagues (2023) reported that obese mice given SLU-PP-332 ran longer, oxidized more fat, and showed improved metabolic markers.
Comparing the Two
The biggest difference is directness. 5-Amino-1MQ works by removing a brake on NAD+. SLU-PP-332 works by stepping on a gene-expression accelerator. One protects an existing resource. The other commands the cell to build more capacity.
A second difference is research depth. Both are mostly preclinical, but 5-Amino-1MQ has been studied for longer and across more disease models. SLU-PP-332 is newer, with most published work coming from the last few years and no human clinical trials yet.
What's still being studied: long-term safety, off-target effects, and whether either compound produces durable metabolic changes once dosing stops. These compounds are sold strictly for in vitro laboratory research and are not approved for human consumption.